Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$92.27
$0.23(0.28%)
At close: 4:00 PM EDT
$92.27
$0.23(0.28%)
Day’s Range― - ―
52-Week Range$44.42 - $151.02
Previous CloseN/A
Volume428.06K
Average Volume (3M)817.30K
Market Cap
$4.12B
Enterprise Value$5.74K
Total Cash (Recent Filing)$754.04M
Total Debt (Recent Filing)$754.38M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 18, 2026EPS Estimate
-1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.29
Shares Outstanding48,931,908
10 Day Avg. Volume925,792
30 Day Avg. Volume817,302
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.12
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$160.50Price Target Upside73.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.85
Revenue Forecast (FY)$38.21M
Bulls Say, Bears Say
Bulls Say
Regulatory And Guideline ValidationFDA approval and NCCN Category 1 endorsement materially strengthen the product’s clinical credibility and prescribing position. This validation can support adoption, payer discussions, and broader physician confidence, creating a durable foundation for commercialization beyond a single readout.
Strong Clinical Efficacy And TolerabilityThe combination of roughly doubled progression-free survival and markedly lower treatment discontinuation indicates meaningful differentiation against an established comparator. A stronger efficacy-tolerability profile may improve treatment persistence and support durable demand across the targeted breast-cancer population.
Commercial Launch Readiness And Market OpportunityCommercial infrastructure, payer preparation, and an identified patient population give Celcuity a credible path from regulatory success to product revenue. The estimated market opportunity is substantial, while the established sales organization can support broader and more consistent physician access over time.
Bears Say
Pre-revenue Model With Widening LossesThe absence of reported revenue leaves Celcuity dependent on financing and future commercialization to fund operations. Rapidly widening losses increase the amount of capital required before the business can become self-sustaining, making execution and future revenue conversion especially important.
Higher Leverage And Negative EquityA heavily levered, pre-revenue balance sheet reduces financial flexibility and increases dependence on successful commercialization or additional capital. Negative equity and a larger debt burden can raise refinancing pressure, interest obligations, and the potential for future dilution if funding needs persist.
Manufacturing And Reimbursement Execution RiskCommercial success depends not only on clinical validation but also on reliable supply and timely market access. Delayed FDA clearance for the secondary site could constrain manufacturing flexibility, while payer and formulary negotiations may slow uptake even with favorable treatment guidelines.
Celcuity News
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $44.42 and its highest was $151.02 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $4.12B.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Nov 18, 2026 which is in 53 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Aug 13, 2026. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$0.275.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -1.4.
How many shares outstanding does Celcuity have?
Celcuity has 48,931,908 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$1.44 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went up 6.236%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$160.50 (73.95% Upside)
$160.50 (73.95% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 93%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 72.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $317.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
351.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Celcuity
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CELC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: regulatory approval (FDA), rapid NCCN Category 1 endorsement, robust phase 3 efficacy (large PFS gains and lower discontinuation vs comparator), commercial launch readiness, a sizeable addressable market (> $6B annual TAM) and a fortified balance sheet with a cash runway into 2029. Offsetting risks include materially higher operating losses and SG&A tied to launch investments, increased near-term cash burn, conditional reliance on FDA review for a secondary manufacturing site (supply risk), and limited real-time utilization visibility for an IV therapy. Overall, the operational and clinical wins materially outweigh the financial and execution risks described.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$160.50
▲(73.95% Upside)
Technical Analysis
Ownership Overview
18.33% Insiders
12.24% Mutual Funds
11.92% Other Institutional Investors
46.28% Public Companies and Individual Investors